HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Fibrates lower triglycerides and may reduce CVD risk in metabolic syndrome

Gokhan Can · Mar 01, 2024 · ♥ 5 reactions · 3 comments · original Facebook post
LDL, ApoB & lipid panelPCSK9, ezetimibe & newer drugs
AI summary & key facts

Brief overview of fibrates (fenofibrate, gemfibrozil), PPAR-alpha agonists that lower triglycerides, raise HDL and have anti-inflammatory effects. Meta-analyses and real-world data suggest a role for CVD risk reduction in people with metabolic syndrome, especially high triglycerides and low HDL. A 2020 review notes that several RCTs did not show clear benefit overall.

Fibrates


Paper · Diabetes Metab J · 2020Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction.Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an "add on" to statin therapy. However, subsequent analyses by major clinical trials,…ncbi.nlm.nih.gov

The article by Kim and Kim (2020) provides an overview of the evidence supporting the use of fibrate drugs, particularly fenofibrate, for cardiovascular risk reduction in patients with metabolic syndrome and atherogenic dyslipidemia (elevated triglycerides and low HDL cholesterol).

Mechanism of Action

Residual Cardiovascular Risk

Clinical Trials of Fibrates

Potential Role of Fibrates in Metabolic Syndrome

Real-World Data on Fibrate Therapy

Conclusions

In summary, Kim and Kim (2020) provide a review indicating fibrates should be considered as adjunctive therapy to statins for residual cardiovascular risk reduction in patients with atherogenic dyslipidemia associated with metabolic syndrome. Additional evidence is still needed from randomized trials focused on this particular high-risk patient subgroup.


Brian Kennedy on Gemfibrozil (2022)

▶Video · YouTube · Longevity Summit DublinMechanisms of Action of Longevity Therapeutics – Brian Kennedy at Longevity Summit Dublin 2023Mechanisms of Action of Longevity Therapeutics – Brian Kennedy at Longevity Summit Dublin 2023youtube.com

Meta analyses of Fibrates:

  1. Checking your browser - reCAPTCHA (ncbi.nlm.nih.gov)
  1. The Lancet article (The Lancet)

Gemfibrozil lowers HS-CRP and Trigs:

  1. J Clin Endocrinol Metab article (J Clin Endocrinol Metab)
  1. Link to ahajournals.org (ahajournals.org)

Gemfibrozil shows some longevity benefits in mice:

  1. Mechanisms of Action of Longevity Therapeutics – Brian Kennedy at Longevity Summit… (Longevity Summit Dublin)
  1. Gemfibrozil, a lipid-lowering drug, improves damage in a mouse model of aging (Rapamycin Longevity News)

Research cited

#fibrates#triglycerides#cholesterol#cardiovascular#metabolicsyndrome#statins#aging#aminoacids
← newer: Alpha-ketoglutarate (AKG): longevity data in worms and mice,older: Question about eating sushi and sashimi daily →